Key points from article :
Genesis Therapeutics has raised $200 million in an oversubscribed Series B funding round.
The company leverages AI to identify new high-value and previously unexplored therapeutic targets, often deemed “undruggable.”
New funding will propel some AI-generated drug candidates into clinical development, and also facilitate expansion of its pipeline.
Funding round brings the total raised by the Genesis to more than $280 million.
The AI platform, Genesis Exploration of Molecular Space (GEMS), uses cutting-edge generative and predictive techniques to discover and optimize small molecule drugs.
GEMS platform assesses the 3D structure and interactions of protein-ligand complexes to make accurate predictions.
Molecular simulation element allows to learn 3D binding dynamics and a molecular generation engine can create novel molecules for each drug program.
“AI presents a potent opportunity to revolutionize the drug discovery process, which often struggles to produce viable drug candidates,” - Evan Feinberg, CEO of Genesis.
